The current guidelines on antiviral treatment for hepatitis B, both in Europe and the United States and in China, consistently recommend nucleoside antiviral therapy. As long as the criteria are met, regardless of the patient’s actual liver damage, age, and the patient’s requirements for fertility, not to mention whether the patient can afford long-term antiviral therapy. In our opinion, antiviral therapy for hepatitis B should focus more on the actual situation of the patient and emphasize the benefits of antiviral therapy, which is also known as cost effectiveness. Because, nucleoside analogs have the following disadvantages: Patients in China also need to pay out of pocket, the cost of antiviral drugs alone ranges from 5,000 yuan to more than 10,000 yuan a year, which is a greater burden for many patients with chronic hepatitis B. It is difficult to stop the drugs. Previously, about the major triple-positive patients can consider stopping the drugs if the seroconversion lasts for more than six months after antiviral treatment, and some drugs even claim to have a high seroconversion rate. However, it has been proven that many patients still rebound after stopping the medication after seroconversion. Since the concept of antiviral treatment for hepatitis B is derived from the antiviral treatment for AIDS, long-term medication is bound to become a trend. However, it is unimaginable that a young person in his or her 20s would be burdened with a lifetime of antiviral therapy.